Literature DB >> 21226860

Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury.

C Sølling1, A T Christensen, S Krag, J Frøkiaer, L Wogensen, J Krog, E K Tønnesen.   

Abstract

BACKGROUND: Erythropoietin (EPO) is a cytokine with organ-protective properties. We hypothesized that EPO could attenuate acute renal dysfunction and inflammation in a porcine model of ischemia-reperfusion (IR). Furthermore, we aimed to characterize the impact of EPO on systemic and renal hemodynamics, and renal oxygen consumption.
METHODS: Twenty-four pigs were randomly assigned to three groups: (1) EPO (5000 IU/kg) administered intravenously before IR (n=9), (2) placebo administered before IR (n=9), or (3) sham group, anesthetized and operated on only (n=6). IR was induced by clamping the left renal artery for 45 min. Hemodynamics and renal blood flow (RBF) were analyzed continuously. Glomerular filtration rate (GFR), renal oxygen consumption, and plasma cytokines (IL-1β, IL-6, IL-8, IL-10, and TNF-α) were analyzed hourly. Renal biopsies were analyzed for cytokine content and apoptosis.
RESULTS: GFR was higher during reperfusion in the EPO group than in the placebo group (P<0.01). No differences between the IR groups were found in hemodynamics, RBF, oxygen consumption, or renal apoptosis. The levels of TNF-α in the plasma (P=0.036) and the levels of TNF-α and IL-10 in the renal cortex (P=0.04 and P=0.01, respectively) were lower in the EPO group compared with the sham group.
CONCLUSION: EPO attenuated the renal dysfunction as estimated as GFR. This effect was not related to changes in the hemodynamics. The immunomodulatory effects of EPO were manifested as decreased levels of TNF-α and IL-10 in renal biopsies and TNF-α levels in plasma.
© 2011 The Authors. Journal compilation © 2011 The Acta Anaesthesiologica Scandinavica Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21226860     DOI: 10.1111/j.1399-6576.2010.02369.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  17 in total

1.  Carbamylated erythropoietin-FC fusion protein and recombinant human erythropoietin during porcine kidney ischemia/reperfusion injury.

Authors:  Šárka Matějková; Angelika Scheuerle; Florian Wagner; Oscar McCook; José Matallo; Michael Gröger; Andrea Seifritz; Bettina Stahl; Brigitta Vcelar; Enrico Calzia; Michael Georgieff; Peter Möller; Hubert Schelzig; Peter Radermacher; Florian Simon
Journal:  Intensive Care Med       Date:  2013-01-05       Impact factor: 17.440

Review 2.  Experimental models of acute kidney injury for translational research.

Authors:  Neil A Hukriede; Danielle E Soranno; Veronika Sander; Tayla Perreau; Michelle C Starr; Peter S T Yuen; Leah J Siskind; Michael P Hutchens; Alan J Davidson; David M Burmeister; Sarah Faubel; Mark P de Caestecker
Journal:  Nat Rev Nephrol       Date:  2022-02-16       Impact factor: 42.439

3.  Remote conditioning or erythropoietin before surgery primes kidneys to clear ischemia-reperfusion-damaged cells: a renoprotective mechanism?

Authors:  David S Gardner; Simon J M Welham; Louise J Dunford; Thomas A McCulloch; Zsolt Hodi; Philippa Sleeman; Saoirse O'Sullivan; Mark A J Devonald
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-12

Review 4.  Bridging Translation by Improving Preclinical Study Design in AKI.

Authors:  Mark de Caestecker; Ben D Humphreys; Kathleen D Liu; William H Fissell; Jorge Cerda; Thomas D Nolin; David Askenazi; Girish Mour; Frank E Harrell; Nick Pullen; Mark D Okusa; Sarah Faubel
Journal:  J Am Soc Nephrol       Date:  2015-11-04       Impact factor: 10.121

5.  The Impact of Erythropoietin on Short- and Long-Term Kidney-Related Outcomes in Neonates of Extremely Low Gestational Age. Results of a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial.

Authors:  David J Askenazi; Patrick J Heagerty; Robert H Schmicker; Patrick Brophy; Sandra E Juul; Stuart L Goldstein; Sangeeta Hingorani
Journal:  J Pediatr       Date:  2021-01-20       Impact factor: 4.406

6.  Erythropoietin in the critically ill: do we ask the right questions?

Authors:  Oscar McCook; Michael Georgieff; Angelika Scheuerle; Peter Möller; Christoph Thiemermann; Peter Radermacher
Journal:  Crit Care       Date:  2012-09-26       Impact factor: 9.097

7.  Erythropoietin in the intensive care unit: beyond treatment of anemia.

Authors:  Nimesh Sa Patel; Massimo Collino; Muhammad M Yaqoob; Christoph Thiemermann
Journal:  Ann Intensive Care       Date:  2011-09-23       Impact factor: 6.925

8.  Restoration of Haemoglobin Level Using Hydrodynamic Gene Therapy with Erythropoietin Does Not Alleviate the Disease Progression in an Anaemic Mouse Model for TGFβ1-Induced Chronic Kidney Disease.

Authors:  Lea Pedersen; Lise Wogensen; Niels Marcussen; Claudia R Cecchi; Trine Dalsgaard; Frederik Dagnæs-Hansen
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

9.  Role of ATP-dependent K channels in the effects of erythropoietin in renal ischaemia injury.

Authors:  Tonguc Utku Yilmaz; Nuray Yazihan; Aydın Dalgic; Ezgi Ermis Kaya; Bulent Salman; Mehtap Kocak; Ethem Akcil
Journal:  Indian J Med Res       Date:  2015-06       Impact factor: 2.375

10.  Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study.

Authors:  Sophie de Seigneux; Belen Ponte; Lucien Weiss; Jérôme Pugin; Jacques André Romand; Pierre-Yves Martin; Patrick Saudan
Journal:  BMC Nephrol       Date:  2012-10-03       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.